Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 15/20 | 0.35 |
| ▸ | FEN1 | P39748 | 11/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 10/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | GCK | P35557 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4823987 | 0.90 | CTSC (0.40) | SMN1; SMN2 | |
| SCHEMBL4826952 | 0.80 | GRM4 (0.44) | GRM4TAAR1SMN1; SMN2 | |
| SCHEMBL4824852 | 0.80 | TAAR1 (0.43) | GRM4TAAR1 | |
| SCHEMBL4826878 | 0.80 | TAAR1 (0.43) | GRM4TAAR1 | |
| SCHEMBL4821417 | 0.80 | LMNA (0.44) | TAAR1MAPK1SMN1; SMN2 | |
| SCHEMBL4818770 | 0.79 | GRM4 (0.38) | GRM4TAAR1SMN1; SMN2 | |
| SCHEMBL4824909 | 0.79 | SMN1; SMN2 (0.45) | SMN1; SMN2 | |
| SCHEMBL4818242 | 0.78 | ATM (0.34) | GRM4TAAR1SMN1; SMN2 | |
| SCHEMBL4827325 | 0.77 | ANPEP (0.39) | TAAR1 | |
| SCHEMBL4819687 | 0.76 | PEPD (0.36) | GRM4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070032484-A1 | Cathepsin K inhibitors | ROCHE PALO ALTO LLC | 2007-02-08 | — | — | US | claimed |
| US-7358373-B2 | Cathepsin K inhibitors | ROCHE PALO ALTO LLC (US) | 2008-04-15 | — | — | US | disclosed |
| US-20070032484-A1 | Cathepsin K inhibitors | ROCHE PALO ALTO LLC | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032484-A1 | Cathepsin K inhibitors | CTSK, CTSS, CTSF | ALOX5AP 4230/4885FEN1 3206/4885ALOX5 4552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.